Department of Psychiatry, Tri-Service General Hospital Beitou Branch, National Defense Medical Center, Taipei, 114, Taiwan.
Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, 802, Taiwan.
BMC Cardiovasc Disord. 2024 Nov 9;24(1):628. doi: 10.1186/s12872-024-04280-5.
We explored if the administration of fluoxetine, recognized for its potential in adipocyte browning, entails a differential risk of coronary heart disease (CHD) in comparison to other SSRI medications.
Using the National Health Insurance Research Database of Taiwan from 2000 to 2013, we conducted a retrospective cohort study. The exposure cohort comprised individuals prescribed fluoxetine for over 90 days (n = 2,228). Conversely, those administered other SSRIs (excluding fluoxetine) for a duration surpassing 90 days were designated as the non-exposed cohort (n = 8,912). CHD incidence served as our primary outcome measure, and we employed Cox proportional hazards models to scrutinize the relationship between fluoxetine exposure and CHD development rates.
Compared with the non-exposed cohort, the fluoxetine use had a significantly decreased 21% risk of developing CHD in the exposed cohort (adjusted hazard ratio: 0.79%, 95% confidence interval: 0.68-0.92). Noticeably, results indicated that there was an inverse association between the fluoxetine exposure and the risk of CHD, regardless of whether men, women or other age groups.
Our findings suggest that clinical use of fluoxetine was associated with a 21% reduced risk of CHD relative to other SSRI prescriptions.
我们探究了氟西汀（因其在脂肪细胞棕色化方面的潜力而备受认可）的使用是否会带来相较于其他 SSRI 药物不同的冠心病（CHD）发病风险。
我们利用台湾 2000 年至 2013 年的全民健康保险研究数据库，开展了一项回顾性队列研究。暴露队列包括接受氟西汀治疗超过 90 天的个体（n=2228）。相比之下，接受其他 SSRIs（不包括氟西汀）治疗超过 90 天的个体被归入非暴露队列（n=8912）。CHD 发病率是我们的主要结局指标，我们采用 Cox 比例风险模型来分析氟西汀暴露与 CHD 发生率之间的关系。
与非暴露队列相比，暴露队列中氟西汀的使用使 CHD 发病风险显著降低了 21%（调整后的危险比：0.79%，95%置信区间：0.68-0.92）。值得注意的是，无论男性、女性或其他年龄组，结果均表明氟西汀暴露与 CHD 风险之间呈负相关关系。
我们的研究结果表明，与其他 SSRI 处方相比，临床使用氟西汀与 CHD 风险降低 21%相关。
